- Owns worldwide rights for patented formulations and drug delivery technologies
- Develops and commercializes therapeutic pharmaceuticals and nutraceuticals
- Strategic agenda to become one of world’s only vertically integrated cannabis biotechs
With worldwide rights for unique drug delivery platforms in place, Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) is rapidly building a disruptive, vertically integrated biotechnology company. Advancing this agenda, the company recently announced that it has retained Cannabis Compliance Inc. to submit an application to Health Canada for a dealer’s license on behalf of Pivot’s acquisition target, Agro-Biotech Inc. (http://cnw.fm/0K5Xn).
In February, Pivot announced that its entry into a letter of intent for the proposed acquisition of licensed cannabis producer Agro-Biotech (http://cnw.fm/cvP6W), which operates a fully licensed indoor hydroponic cannabis production facility that’s on track to expand its capacity 10,000 kg per year by the end of this year. Upon completion of the proposed acquisition, the dealer’s license will enable Pivot (through Agro-Biotech) to conduct research and store cannabis derivatives that are not currently covered under the Access to Cannabis for Medical Purposes Regulations.
With the acquisition of Agro-Biotech, Pivot Pharmaceuticals will control the entire manufacturing process from seed to medical derivatives and capture margins along the entire supply chain. The dealer’s license will move Pivot another step closer to becoming one of the only vertically integrated cannabis biotech companies in the world. Pivot is already a differentiated player in the Canadian cannabis industry with its unique approach to enhanced dosing and bioavailability of cannabinoids, and the company’s position in the market will only be bolstered by the acquisition.
Pivot Pharmaceuticals has assembled cutting-edge drug delivery technologies that assist both effectiveness and efficacy of medicinal cannabinoids and have potential applications across other drug categories. Pivot’s patent pending topical transdermal drug delivery technology platform, BiPhasix™, has been shown to significantly enhance the bioavailability of various drugs, leading to improved clinical outcomes. The company also acquired worldwide rights to Solmic Solubilisation Technology Platform, which allows active ingredients to become water-soluble without changing their composition or nature, significantly enhancing drug uptake.
With proven pharmaceutical and patented formulation and delivery technologies, Pivot is well positioned in an important, growing vertical of the cannabis industry and represents a compelling opportunity in the biotechnology sector. This latest announcement by Pivot enhances the opportunity.
For more information, visit the company’s website at www.PivotPharma.com
More from CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.cannabisnewswire.com